Mesigyna is commonly used in contexts involving fertility management, representing the primary therapeutic area for this medication.

The medication is primarily used to help with sustained fertility control and is relevant for easing symptoms related to common hormone-driven disturbances. This generally helps with easing symptoms related to recurrent menstrual cramping (dysmenorrhea), supports managing cycle irregularities, and may assist with the distressing manifestation of heavy menstrual bleeding (menorrhagia).

This form of treatment supports independence from the need for daily dosing, a benefit considered relevant in the context of long-term family planning. The medication plays a role in managing symptoms that interfere with daily functioning and supports general well-being during symptomatic phases.

Quick Fact: Relief for Cyclical Discomfort
Mesigyna is commonly used to help with menstrual pain and heavy menstrual bleeding, offering supportive relief during recurrent episodes.

Regulatory References

1. WHO Prequalification Summary on Estradiol Valerate/Norethisterone Enantate

Mesigyna is intended for use by healthy women of reproductive age who seek hormonal contraception and do not have specific contraindications documented in official regulatory labeling. The eligibility profile is strictly defined by a list of absolute exclusions.

Populations for Whom Use is Prohibited (Contraindicated)

Official regulatory documents state that Mesigyna must not be used by women with the following specific health conditions or states:

• Current or History of Thromboembolic Events: This includes deep vein thrombosis, pulmonary embolism, stroke, or heart attack, or conditions that pose a severe risk for such events, like severe hypertension or diabetes with vascular damage.
• Hormone-Sensitive Malignancy: Known or suspected current or past breast cancer or other cancers that may be influenced by estrogen.
• Severe Liver Disease or Tumors: The presence of severe liver disease where function has not returned to normal, or the presence of liver tumors (benign or malignant).
• Pregnancy Status: Known or suspected pregnancy is a formal contraindication.
• Other Exclusions: Undiagnosed vaginal bleeding and hypersensitivity to the active ingredients are also listed as reasons for exclusion.

Age and Smoking: Women aged 35 years or older who smoke heavily are strongly advised to use alternative methods, as this combination significantly increases cardiovascular risk, often rendering use contraindicated. The official eligibility profile is therefore structured around critical exclusions related to vascular, hepatic, and cancer history.

Interaction Map: Interactions with other medicines and products — official regulatory information for Mesigyna

---

Interaction scope

Property	Value
Medicinal product categories with documented interactions	Hepatic Enzyme Modulators; Anticoagulants; Antidiabetic Agents; HCV Direct-acting Antivirals.
Specific interacting medicines (if explicitly listed)	Rifampicin, Carbamazepine, Phenytoin, Ketoconazole, Ritonavir, ombitasvir/paritaprevir/ritonavir pm dasabuvir.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic: CYP3A4 Induction/Inhibition. Pharmacodynamic: Altered glucose tolerance and coagulation effects.
Timing-based interaction rules (if applicable)	Not applicable; no mandatory separation rules are documented for this depot preparation.
Population-specific interaction notes (if applicable)	Interactions are generally noted to be more significant in patients with impaired liver function.
Interaction-related restrictions	Contraindicated with specific Hepatitis C combination regimens.

---

Interaction classifications (high-level)

Property	Value
Interaction severity classification (as defined in official documents)	Contraindicated; Clinically Significant.
Regulatory basis (EMA / FDA / etc.)	EMA and FDA regulatory labels for combined hormonal contraceptives.
Interaction-context constraints (as defined in official documents)	Risk of reduced contraceptive effectiveness (with inducers) or increased side effects (with inhibitors).

---

Resulting interaction structure

Official interaction statements:

• Co-administration with strong CYP3A4 inducers (e.g., Rifampicin, Phenytoin, St. John's wort) may decrease the plasma concentrations of the estrogen component, with the potential for reduced contraceptive effectiveness.
• Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir, Grapefruit juice) may increase the plasma concentrations of the estrogen component, potentially resulting in an increase in side effects.
• The product is contraindicated for co-use with specific combinations of Hepatitis C Direct-acting Antivirals, including ombitasvir/paritaprevir/ritonavir combinations, due to the regulatory concern for liver enzyme elevations.
• The hormonal components may alter the therapeutic effect of other medications, including a modification of glucose tolerance and an effect on the action of anticoagulants.

Connection to the overall interaction profile (3 sentences):

Official regulatory documents define the product’s interaction structure primarily through pharmacokinetic mechanisms, identifying substances that induce or inhibit the CYP3A4 metabolic pathway to formally describe changes in hormone exposure. This regulatory framework outlines a direct relationship between co-administration and the risk of either decreased contraceptive efficacy or increased side effects. The profile explicitly includes contraindicated combinations with certain HCV regimens and notes pharmacodynamic effects on anticoagulants and antidiabetic agents, as documented in the label.

How Mesigyna Works: Mechanism of Action

Mesigyna, a combined hormonal injection, acts through synergistic modulation across three primary mechanistic domains to influence the reproductive axis.

Central Suppression of the HPO Axis

This mechanism targets the Hypothalamic-Pituitary-Ovarian (HPO) axis. The synthetic hormones initiate a negative feedback effect on the pituitary gland, resulting in the suppression of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) release. This action blocks the key signaling sequence required for follicular maturation and the subsequent LH surge, leading to the physiological consequence of blocking the ovarian cycle's ovulatory signal.

Regulation of Cervical Barrier Function

The progestin component modulates the humoral pathways controlling the function of the cervical glandular system. This binding interaction alters the cervical mucus composition, making it thicker and less permeable. The resulting change constitutes a physical and biochemical block that restricts sperm passage and limits the probability of fertilization.

Modulation of Endometrial Receptivity

Through combined hormonal signaling, the drug influences the endometrial lining (uterus), creating a non-proliferative hormonal environment. This causes atrophic changes in the tissue, resulting in a thin internal environment that is unsuitable for the cell adherence and signaling necessary for implantation.

Mesigyna is administered as a Combined Injectable Contraceptive through the deep intramuscular (IM) route only. This administration method is essential to its function as a depot preparation. The standard regimen involves the use of one fixed-dose ampoule containing 50 mg Norethisterone enanthate and 5 mg Estradiol valerate per cycle. Administration must always be performed by a healthcare professional due to the technical requirements of the deep IM injection, which must be performed slowly into a large muscle mass, such as the gluteal region.

The foundational principle of Mesigyna’s usage is its continuous cyclic administration. The first injection is precisely timed to occur between Day 1 and Day 5 of the woman's natural menstrual cycle. Subsequent injections must follow a rigid schedule, repeated every 30 days, with a minimal interval of 27 days and a maximum interval of 33 days (30 ± 3 days).

Maintaining this frequency is critical for continuous use. If the required 33-day maximum interval is exceeded, the injection can still be administered after pregnancy is ruled out, but instructions require the use of supplementary non-hormonal contraception for the following seven days. The product is intended for long-term use in women of reproductive age and is not indicated for administration before menarche or following menopause.

Mesigyna: Overview of Studies

Evidence for Use in Contraception

Research examined the use of Mesigyna was studied for contraception primarily through short-term and intermediate-term comparative clinical studies and Randomized Controlled Trials (RCTs). These studies monitored outcomes such as the incidence of pregnancy under both perfect-use and typical-use conditions in women seeking reversible contraception. Studies monitored outcomes related to pregnancy occurrence and the time to return of fertility.

Findings describe patterns observed in these studies, reporting measurements of pregnancy rates, often communicated using calculations like the Pearl Index. Studies also reported how participants’ menstrual bleeding patterns evolved in the observed populations during the use of the injection. Research also explored outcomes measured during the study period, such as continuation and discontinuation rates. This body of evidence contributes to the broader evidence landscape related to injectable contraceptives.

Comparative Study Findings

Comparative research examined Mesigyna against other birth control methods, such as combined oral contraceptive pills and other types of injectable contraceptives. These studies monitored outcomes related to continuation rates and participant choice between different methods. Other outcomes observed in these studies included patterns in bleeding and documented side effects.

Long-Term Studies and Follow-Up Data

Research examined the duration of continuous use of Mesigyna in various study settings. A key focus of research examined the time required for a person’s fertility to return after the last injection was administered. This was studied in observational settings that monitored outcomes following cessation of the injection. Long-term effects are not fully established for individuals who use the injection continuously for many years. Furthermore, there is limited information for long-term outcomes concerning physiological changes that may be monitored after many years of continuous exposure.

What is Still Uncertain About Mesigyna

The broader evidence landscape contributes to understanding symptom patterns, but several areas still present uncertainty. Long-term effects are not fully established, particularly concerning use for periods greater than five years. Comparative evidence is lacking for certain new contraceptive formulations, and subgroup findings are uncertain for women with specific medical conditions. Research provides insight into short-term changes, but there is limited information for long-term outcomes, indicating that data are still emerging.

Common questions about Mesigyna (FAQ)

Q: Does Mesigyna cause depression or mood changes?

Official product information states that depressive mood and general mood changes are listed among the commonly reported side effects. This means that these feelings have been observed in women using the medication. It is noted that hormonal changes can sometimes be associated with these feelings.

Q: Does this injection cause weight gain?

According to the official regulatory documents, weight increase is described as a commonly reported adverse reaction. This is one of the systemic effects that has been observed in women using Mesigyna, along with other common side effects like headaches and nausea.

Q: Does Mesigyna cause acne or increase hair growth?

The product literature includes acne and hirsutism among the reported undesirable effects. Hirsutism refers to the growth of excessive or unwanted hair in a male-like pattern. These effects are listed as possible reactions to the hormonal components.

Q: Is this injection safe for women of all ages, including teenagers?

Mesigyna is intended for the prevention of pregnancy in women of childbearing age. Official regulatory documents state that the injection is not indicated for administration before menarche, which is the time when a woman begins having her menstrual cycle.

Q: Can I use Mesigyna while breastfeeding?

Official regulatory guidance states that the use of Mesigyna is generally not recommended during breast-feeding. This caution is noted because the hormones may potentially reduce the quantity and change the composition of breast milk, and small amounts of the steroids may pass to the infant.

Q: Can Mesigyna be used as emergency contraception?

The official therapeutic indication for Mesigyna is solely Contraception, meaning the prevention of pregnancy through scheduled use. Regulatory documents specify that this product is not indicated for use as emergency contraception.

Q: Do I need to use a backup method with the first injection?

Regulatory administration guidelines describe the need for a non-hormonal back-up method of contraception, such as condoms. Official documents state this additional protection is required for the first seven days following the initial injection to ensure continuous contraceptive efficacy.

How to Store and Dispose of Mesigyna

Official regulatory documents define strict requirements for storing and handling Mesigyna (norethisterone enanthate and estradiol valerate) to maintain its chemical stability and efficacy.

Storage Requirements

Storage Classification	Requirement
Temperature Control	Do not store above 30 C.
Freezing	Do not freeze.
Light Protection	Store vials in the original carton to protect from light.

Handling and Disposal

Storage must always be in the original package to ensure the product remains protected from light exposure, which can cause degradation. The temperature constraint dictates that the medicine must be kept in a cool, dry place and shielded from excessive heat. For disposal, no special instructions are typically documented beyond adherence to local regulations for discarding unused or expired pharmaceutical waste.